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Abstract
More than 30 Curcuma species (Zingiberaceae) are found in Asia, where the rhizomes of these
plants are used as both food and medicine, such as in traditional Chinese medicine. The plants are
usually aromatic and carminative, and are used to treat indigestion, hepatitis, jaundice, diabetes,
atherosclerosis and bacterial infections. Among the Curcuma species, C. longa, C. aromatica and C.
xanthorrhiza  are popular. The main constituents of Curcuma  species are curcuminoids and
bisabolane-type sesquiterpenes. Curcumin is the most important constituent among natural
curcuminoids found in these plants. Published research has described the biological effects and
chemistry of curcumin. Curcumin derivatives have been evaluated for bioactivity and structure-
activity relationships (SAR). In this article, we review the literature between 1976 and mid-2008 on
the anti-inflammatory, anti-oxidant, anti-HIV, chemopreventive and anti-prostate cancer effects of
curcuminoids. Recent studies on curcuminoids, particularly on curcumin, have discovered not only
much on the therapeutic activities, but also on mechanisms of molecular biological action and major
genomic effects.
Background
Curcuma species
In Asia zingiberaceous plants have been used since
ancient times as both spices and medicines, such as in tra-
ditional Chinese medicine. Within this plant family, vari-
ous Curcuma species, particularly C. longa (turmeric), C.
aromatica (wild turmeric), and C. xanthorrhiza (Javanese
turmeric), have been used. The rhizomes of these plants
are usually aromatic and carminative, and are used to treat
indigestion, hepatitis, jaundice, diabetes, atherosclerosis
and bacterial infections [1,2].
Isolated from Curcuma  plants, various bioactive com-
pounds are useful medicines. For example, curcumol (1)
(Figure 1), a sesquiterpene isolated from C. aromatica, is
useful in treating cervical cancer [3].
The rhizomes of C. longa, commonly known as turmeric,
are used worldwide as spices (e.g. curry), flavoring agents,
food preservatives and coloring agents. They are also used
as medicines to treat inflammation and sprains in India,
China and other Asian countries. Curcuminoids, the main
components in Curcuma species, share a common unsatu-
rated alkyl-linked biphenyl structural feature and are
responsible for their major pharmacological effects. The
biological and chemical properties of curcuminoids were
reported [4-9].
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Curcuminoids in C. longa and other Curcuma species are
mainly curcumin (2), bis-demethoxycurcumin (3) and
demethoxycurcumin (4) (Figure 1), among which curcu-
min is the most studied and shows a broad range of bio-
logical activities. This article highlights some of the
important biological properties of curcumin and its deriv-
atives, as well as their structure-activity relationships
(SAR).
C. xanthorrhiza is used as a tonic in Indonesia and a chol-
eric drug in Europe. Apart from curcuminoids, this species
contains bioactive bisabolane-type compounds, such as
α-curcumen (5), ar-turmerone (6) and xanthorrhizol (7)
(Figure 2). These three compounds demonstrated strong
anti-cancer activities against Sarcoma 180 ascites in mice
[10-15]. In addition, xanthorrhizol (7) exhibited antibac-
terial activity [16].
Curcumin and its biological activities
Curcumin (2) [diferuloylmethane, 1,7-bis-(4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione] is the main
yellow constituent isolated from C. longa and other Cur-
cuma species. It was first isolated in 1870, but its chemical
structure had not been elucidated until 1910 [17] and was
subsequently confirmed by synthesis. Curcumin has a
unique conjugated structure including two methylated
phenols linked by the enol form of a heptadiene-3,5-dike-
tone that gives the compound a bright yellow color.
In addition to its well known anti-inflammatory effects,
curcumin also possesses other therapeutic effects on
numerous biological targets [18]. Other activities of cur-
cumin include reduction of blood cholesterol level, pre-
vention of low density lipoprotein (LDL) oxidation,
inhibition of platelet aggregation, suppression of throm-
bosis and myocardial infarction, suppression of symp-
toms associated with type II diabetes, rheumatoid
arthritis, multiple sclerosis and Alzheimer's disease, inhi-
bition of human immunodeficiency virus (HIV) replica-
tion, enhancement of wound healing, increase of bile
secretion, protection from liver injury, cataract formation
and pulmonary toxicity and fibrosis, exhibition of anti-
leishmaniasis and anti-atherosclerotic properties, as well
as prevention and treatment of cancer [18]. Curcumin is
non-toxic even at high dosages, and has been classified as
'generally recognized as safe' (GRAS) by the National Can-
cer Institute [19]. There were also studies focusing on the
biology and action mechanisms of curcumin [18,20].
Synthetic bioactive curcumin analogs were developed
from the natural compound based on the structure-activ-
ity relationship (SAR) studies and optimization of com-
pounds as drug candidates in their relations to different
Structures of curcumol and curcuminoids in Curcuma species Figure 1
Structures of curcumol and curcuminoids in Curcuma species.
Structure of bisabolane-type compounds in Curcuma species Figure 2
Structure of bisabolane-type compounds in Curcuma 
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activities, including anti-inflammatory, anti-oxidant, anti-
HIV, chemopreventive and anti-cancer (prostate cancer),
as well as possible action mechanisms.
Anti-inflammation
Anti-inflammatory activity
Curcumin inhibits the metabolism of arachidonic acid,
activities of cyclooxygenase, lipoxygenase, cytokines
(interleukins and tumor necrosis factor), nuclear factor-
κB (NF-κB) and release of steroids [21]. Curcumin stabi-
lizes lysosomal membranes and causes uncoupling of oxi-
dative phosphorylation. It also possesses strong oxygen
radical scavenging activity, which confers anti-inflamma-
tory properties. In various animal studies, a dose of curcu-
min at 100–200 mg per kilogram of body weight
exhibited anti-inflammatory activity. The same dose did
not have obvious adverse effects on human systems. Oral
median lethal dose (LD50) in mice is higher than 2.0 g/kg
of body weight [21].
Pro-inflammatory cytokines, such as interleukin-1β (IL-
1β) and tumor necrosis factor-α (TNF-α), play key roles in
the pathogenesis of osteoarthritis (OA). Anti-inflamma-
tory agents that can suppress the production and catabolic
actions of these cytokines may have therapeutic effects on
OA and some other osteoarticular disorders. Accordingly,
curcumin was examined for its effects on IL-1β and TNF-
α signaling pathways in human articular chondrocytes in
vitro  [22]. Expression of collagen type II, integrin β1,
cyclo-oxygenase-2 (COX-2) and matrix metalloprotein-
ase-9 (MMP-9) genes was monitored by Western blotting.
The effects of curcumin on the expression, phosphoryla-
tion, and nuclear translocation of protein components of
the NF-κB system were studied with Western blotting and
immunofluorescence respectively. The results indicated
that curcumin suppressed IL-1β-induced NF-κB activation
via inhibition of inhibitory protein κBα (IκBα) phospho-
rylation, IκBα degradation, p65 phosphorylation and p65
nuclear translocation. Curcumin also inhibited IL-1β-
induced stimulation of up-stream protein kinase B Akt.
These events correlated with the down-regulation of NF-
κB targets, including COX-2 and MMP-9. Similar data
were obtained when chondrocytes were stimulated with
TNF-α. Curcumin also reversed the IL-1β-induced down-
regulation of collagen type II and β1-integrin receptor
expression. These results indicate that curcumin may be a
naturally occurring anti-inflammatory nutritional agent
for treating OA via suppression of NF-κB mediated IL-β/
TNF-α catabolic signaling pathways in chondrocytes [22].
Curcumin was found to act by diverse anti-inflammatory
mechanisms at several sites along the inflammation path-
way [23].
Anti-inflammatory SAR
The active constituents of C. longa are curcuminoids,
including curcumin (2), demethoxycurcumin (3) and bis-
demethoxycurcumin (4) [24] (Figure 1), among which
curcumin is the most potent anti-inflammatory agent
[25]. In addition to these natural curcuminoids, sodium
curcuminate (8) and tetrahydrocurcumin (9) (Figure 3)
showed potent anti-inflammatory activity at low doses in
carrageenin-induced rat paw edema and cotton pellet
granuloma assays [26]. Other semi-synthetic analogs of
curcumin were screened for anti-inflammatory activity in
the same assays; diacetylcurcumin (10) and tetrabromo-
curcumin (11) (Figure 3) were the most potent [27,28].
Structures of semi-synthetic analogs tested for anti-inflammatory activity Figure 3
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The presence of the β-diketone moiety as a linker between
the two phenyl groups was deemed important for the anti-
inflammatory activity.
Nurfina et al. designed and synthesized 13 symmetrical
curcumin analogs (12–24) [29]. Anti-inflammatory activ-
ity was evaluated by inhibition of carrageenin-induced
swelling of rat paw (Table 1); and the following SAR con-
clusions were drawn: (a) appropriate substituents on the
phenyl rings were found necessary for anti-inflammatory
activity. Unsubstituted compound 12,  ortho-methoxy,
substituted analog 18, and meta-methoxy substituted ana-
log 13 showed no inhibitory activity; (b) proper substitu-
ents at the para-positions of the phenyl rings were also
crucial. A para-phenolic group leads to the most potent
anti-inflammatory activity [compare 3  (p-OH),  21  (p-
CH3), 20 (p-OCH3), 19 (p-Cl) as well as 2 with 22 and 24
with 14]; and (c) size of the substituents adjacent to a
para-phenol was found to be important for potency.
Dimethyl substitution (15) at R2 and R4 enhanced the
activity most, followed by diethyl (16) and dimethoxy
(24). Compound 21 with two isopropyl moieties showed
weaker activity, while 23 with bulky tetrabutyl substitu-
tion at both positions showed no anti-inflammatory
activity.
Cyclovalone (25) and three analogs (26–28) (Figure 4)
having a cyclohexanone or cyclopentanone in the linker
between the two phenyl rings showed anti-inflammatory
activity to inhibit cyclooxygenase [30]. Compounds 26–
28 were more potent than curcumin (2) which was used
as a reference standard. The dimethylated 28 and 26 were
more potent than 27 and 25 respectively, and thus, the
addition of methyl groups on the phenyl rings enhanced
anti-inflammatory activity. The increased size of the cyclo-
alkanone ring, by replacing the cyclopentanone in 27 with
a cyclohexanone in 25, increased inhibitory potency.
However, this effect was not seen in the dimethylated
compounds 28 and 26 respectively, both of which were
comparably potent.
Besides curcumin, other structurally related constituents
of plants in the Zingiberaceae family possess anti-inflam-
matory activity [31]. Examples are the phenolic yakuchi-
nones A and B (29 and 30) isolated from Alpinia oxyphylla
[32-34] (Figure 5).
Anti-oxidation
Anti-oxidant activity
Most natural anti-oxidants can be classified into two types
of compounds, namely phenolic and β-diketone [35]. Ses-
aminol isolated from sesame belongs to the former, while
n-triacontane-16,18-dione isolated from the leaf wax of
Eucalyptus belongs to the latter. Curcumin (2) is one of the
few anti-oxidants that possess both phenolic hydroxy and
β-diketone groups in one molecule. Its unique conjugated
structure includes two phenols and an enol form of a β-
diketone. Therefore, it may have a typical radical trapping
ability and a chain-breaking anti-oxidant activity.
Curcumin is a potent anti-oxidant whose action mecha-
nism is not well understood. However, the nonenzymatic
anti-oxidant process of a phenolic compound is generally
thought to have two stages as follows:
S-OO￿ + AH ↔ SOOH + A￿
A￿ + X￿ → nonradical materials
Where S is the oxidized substance; AH is the phenolic
anti-oxidant; A￿ is the anti-oxidant radical; and X￿ is
another radical species or the same species as A￿ [35].
While the first stage is reversible, the second stage is irre-
versible and must produce stable radical terminated com-
pounds. Structural elucidation of the terminated
compounds may contribute significantly to understand-
ing the mechanism of the phenolic anti-oxidant. It has
recently been shown that dimerization is a main termina-
tion process of the radical reaction of curcumin itself. In
food, the anti-oxidant coexists with large amounts of oxi-
dizable biomolecules, such as polyunsaturated lipids.
These biomolecules were found to produce reactive per-
oxy radicals during their oxidation, which may act as X￿
Table 1: Anti-inflammatory activity data of curcumin derivatives 
Compound R1 R2 R3 R4 ED50 (mg/kg)
2 HO C H 3 OH H 38 ± 4
3 HH O H H 7 3  ±  5
12 HHHH N A
13 HO C H 3 HH N A
14 HO C H 3 OCH3 OCH3 NA
15 HC H 3 OH CH3 13 ± 2
16 HC 2H5 OH C2H5 22 ± 6
17 Hi - C 3H7 OH i-C3H7 58 ± 21
18 OCH3 HHH N A
19 HHC lH N A
20 HH O C H 3 H8 2  ±  7
21 HH C H 3 H8 0  ±  1 8
22 HO C H 3 OCH3 H5 0  ±  2 2
23 H t-C4H9 OH t-C4H9 NA
24 HO C H 3 OH OCH3 28 ± 5
NA: not active
ED50 values are expressed as 'means ± standard deviations'.
R2
R3
OH O
R3
R2
R1
R4 R4
R1Chinese Medicine 2008, 3:11 http://www.cmjournal.org/content/3/1/11
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and couple with the anti-oxidant radical (A￿) in the sec-
ond step of the above anti-oxidation scheme [36].
Anti-oxidant SAR
Curcumin showed both anti-oxidant and pro-oxidant
effects in oxygen radical reactions. Depending on the
experimental conditions, it may act as a scavenger of
hydroxy radicals or a catalyst in the formation of hydroxy
radicals [37-39]. The anti-oxidant effect of curcumin pre-
sumably arises from scavenging of biological free radicals.
The anti-oxidant activities of three natural curcuminoids
(2–4) and their hydrogenated analogs (9, 31, 32) (Figure
6) were examined in three bioassay models, i.e. the lino-
leic acid auto-oxidation model, rabbit erythrocyte mem-
brane ghost system, and rat liver microsome system. The
results obtained from the three models were consistent.
Curcumin (2) and tetrahydrocurcumin (9) had the
strongest anti-oxidant activity among the natural and
hydrogenated curcuminoids respectively [35]. Among all
six compounds, tetrahydrocurcumin (9) showed the high-
est potency, implying that hydrogenation of curcumin-
oids increased their anti-oxidant ability. Absence of one or
both methoxy groups resulted in decreased anti-oxidant
activity in both natural curcuminoids and tetrahydrocur-
cuminoids. In contrast, Sharma et al. reported that the
presence of methoxy groups in the phenyl rings of curcu-
min enhanced anti-oxidant activity [40].
Venkatessan et al. [41] used three models to investigate
the importance of the phenolic hydroxy groups, as well as
other substituents on the phenyl rings of curcuminoids, to
anti-oxidant activity. The three anti-oxidant bioassays
were inhibition of lipid peroxidation, free radical scaveng-
ing activity by the DPPH method, and free radical scav-
enging activity by the ABTS method. The data and
compound structures are shown in Table 2. Generally,
curcumin analogs with a phenolic moiety were more
potent than non-phenolic analogs, and thus, phenolic
substitution is important for anti-oxidant activity. Com-
pound 15, a 4'-hydroxy-3',5'-dimethyl substituted analog,
showed potency in all three bioassays. However, com-
Structures of cyclovalone (25) and three related analogs Figure 4
Structures of cyclovalone (25) and three related analogs.
Structures of yakuchinones A (29) and B (30) Figure 5
Structures of yakuchinones A (29) and B (30).Chinese Medicine 2008, 3:11 http://www.cmjournal.org/content/3/1/11
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pound 23, a 4'-hydroxy-3',5'-di-t-butyl analog, was ten-
fold less potent in the lipid peroxidation assay, indicating
that steric hindrance at the positions flanking the
hydroxyl group decreased anti-oxidative activity. Chang-
ing the 3'-methoxy group in curcumin (2) to an ethoxy
group in 33 had little effect on anti-oxidant activity, but
both compounds were more potent than 3, which does
not have an alkoxy group at the 3'-position. In all three
systems, tetrahydrocurcumin (9) and curcumin (2)
showed comparable activity. This result suggests that
enhanced electron delocalization of the double bonds
may not be essential to anti-oxidant activity of curcumin-
oids.
The anti-oxidant mechanisms of curcumin have been
investigated. The salient finding is that curcumin is a phe-
nolic chain-breaking anti-oxidant, which donates H
atoms from the phenolic groups [42-47]. However, some
contrasting results suggest that H atom donation takes
place at the active methylene group in the diketone moi-
Table 2: Anti-oxidant activity data of curcumin derivatives 
Compound R1 R2 R3 Lipid peroxidation inhibition 
IC50 (μM)
DPPH scavenging IC50 (μM) ABTS scavenging TEAC
3 min 9 min 15 min
2 OCH3 OH H 1.30 20.02 2.61 3.09 3.37
3 H OH H 2.19 32.08 3.04 4.31 4.96
9 structure formula 9 above 1.83 18.22 2.08 2.37 2.52
10 OCH3 OAc H 1.85 NA 1.33 2.01 2.33
12 H H H NA >250 1.57 2.78 3.36
14 OCH3 OCH3 OCH3 15.32 NA 1.90 2.98 3.43
15 CH3 OH CH3 0.63 21.75 0.89 1.13 1.28
20 HO C H 3 H NA >250 2.05 2.04 2.14
21 HC H 3 H NA >250 0.67 1.52 1.96
22 OCH3 OCH3 H NA >250 1.86 2.49 2.67
23 t-C4H9 OH t-C4H9 6.48 23.72 0.81 0.96 1.07
33 OC2H5 OH H 1.11 30.32 2.36 3.07 3.32
34 HS C H 3 H NA NA below 90 1.09 ND ND
IC50 is the concentration required for 50% inhibition of lipid peroxidation or scavenging of DPPH radical. TEAC is the trolox equivalent anti-
oxidation capacity, which is defined as the mM concentration of a trolox solution having the antioxidant capacity equivalent to a 1.0 mM solution of 
the substance under investigation.
NA: not active
ND: not determined.
R1
R2
OH O
R2
R1
R3 R3
H3CO
HO
O O
OH
OCH3
Tetrahydrocurcumin (9)
Structures of tetrahydrocurcuminoids Figure 6
Structures of tetrahydrocurcuminoids.Chinese Medicine 2008, 3:11 http://www.cmjournal.org/content/3/1/11
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ety [48,49]. Ligeret et al. evaluated the effects of curcumin
and numerous derivatives on the mitochondrial permea-
bility transition pore (PTP), which can release apop-
togenic factors from mitochondria to induce apoptosis
[50]. The authors postulated that PTP opening is closely
related to the anti-oxidant property of curcumin. Based on
the data on mitochondria swelling, O2￿ and HO￿ produc-
tion, thiol oxidation and DPPH￿ reduction, the authors
concluded that phenolic groups in curcuminoids are
essential for activity, and are more effective at the para
position than at the ortho position. In addition, an elec-
tron donating group at the ortho position relative to the
phenolic group is also required for activity, while t-butyl
and bulky substituents are not favorable. In contrast, elec-
tron-withdrawing substitution, such as NO2, reduced
activity. Although ferulic acid does not show anti-oxidant
effects, replacing the β-diketone moiety of curcumin with
a cyclohexanone ring attenuated anti-oxidant activity.
Thus, the authors concluded that the β-diketone contrib-
uted to, but could not induce, the activity of curcumin
derivatives. The conclusions agree with the prevailing SAR
for anti-oxidant activity.
However, in one study, a curcumin analog without phe-
nolic and methoxy groups was found to be as potent as
curcumin in terms of scavenging hydroxy radicals and
other redox properties [51]. Wright employed theoretical
chemistry to interpret the controversy [52]; taking into
account the diversity of test free radicals, solvents, and pH
ranges used in the literature. First, he explored the stabili-
ties of curcumin conformers, pointing out that the enol
form is the most stable, followed by the trans-diketo form,
and then the cis-diketo form (Figure 7). Calculations
showed that the phenolic O-H is the weakest bond in cur-
cuminoids. This theoretical approach favors the necessity
of a phenolic OH group for the anti-oxidant activity of
curcumin and its analogs. However, the C-H bond of the
methylene group becomes active when radicals with high
bond dissociation enthalpy, such as methyl and t-butoxy
radicals, are used. Thus, differences among experimental
results can be possibly due to the differences in the attack-
ing radicals used in different bioassay systems.
Anti-HIV
Anti-HIV activity
Oxidative stress is implicated in HIV-infection. It was sug-
gested that plant anti-oxidants may offer protection from
viral replication and cell death associated with oxidative
stress in patients with HIV/acquired immune deficiency
syndrome (AIDS) [53]. Curcumin (2) can inhibit purified
HIV type 1 integrase, HIV-1 and HIV-2 protease, and HIV-
1 long terminal repeat-directed gene expression of acutely
or chronically infected HIV-1 cells. Curcumin can also
inhibit lipopolysaccharide-induced activation of NF-κB, a
factor involved in the activation and replication of HIV-1.
However, curcumin did not show significant efficacy in
clinical trials.
In addition to the lipid soluble component curcumin, tur-
meric also contains the water-soluble extract turmerin
(molecular weight: 24000 Daltons). Neither turmeric nor
turmerin has been studied for anti-HIV activity. In a lim-
ited number of studies, cell viability and p24 antigen
release by CEMss-T cells infected with HIV-IIIB  strain
(acute infection model) and proliferative responses of
human mononuclear cells derived from HIV patients
(chronic infection model) stimulated with phytohema-
toglutinin, concanavalin A, and pokeweed mitogen were
examined in the presence of AZT, curcumin, and tur-
merin. In infective assays, neither turmerin nor curcumin
Structures of curcumin conformers Figure 7
Structures of curcumin conformers.Chinese Medicine 2008, 3:11 http://www.cmjournal.org/content/3/1/11
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individually reduced p24 antigen release or improved cell
viability [53]. However, AZT (5 μM) plus turmerin (800
ng/ml) inhibited infection by 37% and increased cell
numbers by 30%. In the proliferation assay, lymphocytes
from HIV-infected patients showed better inhibition of
mitogen responsiveness to turmerin (800 ng/ml) than
that of AZT at 5 μM or turmerin at 80 ng/ml. Turmerin
inhibited HIV-infected T-cell proliferation and, in combi-
nation with AZT, decreased T-cell infection and increased
cell viability. These data suggest that effective anti-HIV
therapy may be possible using lower, less toxic doses of
AZT in the presence of turmerin [53].
Anti-HIV SAR
In addition to reverse transcriptase and protease, HIV-1
integrase is being explored as a new target for the discov-
ery of effective AIDS treatments. HIV-1 integrase is the
enzyme that catalyzes the integration of the double-
strained DNA of HIV into the host chromosome [54].
Curcumin inhibited this activity of HIV-1 integrase [54].
Other classes of compounds inhibited HIV-1 integrase in
enzyme assays, but few showed specificity against HIV-1
integrase and even fewer were active in cell-based assays
[55]. Curcumin was reported to have moderate activity in
cell-based assays, in addition to its activity in enzyme
assays [56].
Therefore, modified curcumin analogs were developed for
anti-HIV potency as well as action mechanism studies
[54,57]. Mazumder et al. [57] synthesized curcumin ana-
logs (Table 3) as probes to study the mechanism of anti-
HIV-1 integrase. Evidence suggests that curcumin does not
bind to HIV-1 integrase at either the DNA-binding
domain [58] or the binding site of another HIV-1 inte-
grase inhibitor, i.e. NSC 158393 [59]. Compounds with-
out a hydroxy group on the phenyl ring (12, 20) did not
inhibit HIV-1 integrase. Therefore, hydroxy groups on the
phenyl rings are apparently essential for inhibitory activ-
ity. Compounds 35 and 36, which contain two and one
catechol ring respectively, exhibited much greater activity
than curcumin (2), indicating that replacing one or both
methoxy groups on curcumin with hydroxy groups
increased anti-HIV activity. Tetrahydrocurcumin (9), with
a saturated linker between the phenyl groups, did not
show inhibitory activity in this assay, suggesting that an
unsaturated linking group also contributed to activity. In
addition, compound 37, with a unique linker bridging
two catechol rings, showed potency comparable to that of
35 and 36, and greater than that of 2.
In the further SAR investigation of curcumin analogs as
inhibitors of HIV-1 integrase, a syn  disposition of the
C=C=C=O moiety in the linker and a coplanar structure
were found to be important to the integrase inhibitory
activity of curcumin analogs [55]. The experimental
results are consistent with the quantitative structure-activ-
ity relationships (QSAR) computed with MOE (Chemical
Computing Group, Canada) and Cerius2 (Molecular Sim-
ulations, USA) programs [60]. Figure 8 summarizes the
anti-HIV-1 integrase SAR of curcumin analogs. However,
no therapeutic indices were reported for the tested com-
pounds.
Chemoprevention
Chemoprevention is a relatively new concept. It attempts
to intervene at early stages of cancer before the invasive
stage begins [61]. Nontoxic agents are administered to
otherwise healthy individuals who may be at increased
risk for cancer. Some potential diet-derived chemopreven-
tive agents include epigallocatechin gallate in green tea,
Table 3: Anti-HIV integrase activity data of curcumin derivatives 
Compound R1 R2 R3 R4 3-processing IC50 (μM) Strand transfer IC50 (μM)
2 OCH3 OH OCH3 OH 150 140
3 H OH H OH 120 80 ± 20
4 HO H O C H 3 OH 140 120
9 structure formula 9 above >300 >300
12 H H H H >300 >300
20 HO C H 3 HO C H 3 >300 >300
35 OH OH OH OH 6.0 ± 1.5 3.1 ± 0.12
36 OCH3 OH OH OH 18.0 ± 9.0 9.0 ± 3.0
37 structure formula 37 above 9 ± 7 4.0 ± 1.5
IC50 values are expressed as 'means ± standard deviations'.
R3
R4
OH O
R2
R1
H3CO
HO
O O
OH
OCH3
O
O
OH
OH
O OH HO
HO
9 37Chinese Medicine 2008, 3:11 http://www.cmjournal.org/content/3/1/11
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curcumin in curry and genistein in soya. Curcumin dem-
onstrated a wide-range of chemopreventive activities in
preclinical carcinogenic models of colon, duodenum,
fore-stomach, mammary, oral and sebaceous/skin can-
cers. The National Cancer Institute is conducting Phase I
clinical trials of curcumin as a chemopreventive agent for
colon cancer [62]. Curcumin's chemopreventive mecha-
nisms are pleiotropic. It enhanced the activities of Phase 2
detoxification enzymes of xenobotic metabolism, includ-
ing glutathione transferase [63] and NADPH:quinone
reductase [64]. It also inhibited pro-carcinogen activating
Phase 1 enzymes such as cytochrome P450 1A1 [65]. As
regards its mode of chemopreventive action in colon can-
cer, curcumin exhibited diverse metabolic, cellular and
molecular activities including inhibition of arachidonic
acid formation and its further metabolism to eicosanoids
[66].
Anti-prostate cancer
Prostate cancer is the most common cancer among males
in the West [67] and is a complex heterogeneous disease
that affects different men differently. The cause of prostate
cancer is largely unknown. However, androgen and the
androgen receptor (AR) are postulated to play crucial roles
in the development of prostate cancer [68].
Prostate cancer is currently treated with a combination of
surgery, radiation and chemotherapy. The therapeutic
agents used clinically include steroidal anti-androgens,
such as cyproterone acetate, and non-steroidal anti-andro-
gens, such as flutamide and bicartamide. The steroidal
anti-androgens possess partial agonistic activity and over-
lapping effects with other hormonal systems, leading to
complications such as severe cardiovascular problems,
gynecomastia, libido loss and erectile dysfunction [69-
71]. Non-steroidal anti-androgens have fewer side effects
and higher oral bioavailability than steroidal anti-andro-
gens.
While non-steroidal anti-androgens are advantageous,
anti-androgen withdrawal syndrome was found in
patients receiving non-steroidal anti-androgens for several
months [72,73]. Long-term drug usage would lead to
mutation of the AR, and the non-steroidal anti-androgens
may exhibit agonistic activity to the mutant AR [74]. In
addition, the clinically available anti-androgens are una-
ble to kill prostate cancer cells, and within one to three
years of drug administration, the cancer usually develops
into an androgen refractory stage [72-74]. Therefore, new
classes of anti-prostate cancer drugs are urgently needed.
Prostate cancer occurs much less frequently in Asia than in
the West [75], possibly due to dietary differences. Tur-
meric is much more highly consumed as both spice and
medicine in India, Thailand, China and Japan than in the
West. Thus, we and other researchers investigated turmeric
and its constituent curcumin for anti-prostate cancer
effects.
Although curcumin is a well known anti-inflammatory
and anti-oxidant agent, its anti-prostate cancer activity has
not been extensively explored. Over the last decade, our
research group has used curcumin (2) as a lead compound
for the design and synthesis of curcumin analogs as a new
class of potential anti-androgenic agents for the treatment
of prostate cancer as well as for action mechanism studies
[76-81]. Certain curcumin analogs including 38 (JC-9),
39 (4-ethoxycarbonyl curcumin, ECECu) and 40 (LL-80)
(Figure 9), showed potent in vitro cytotoxic activity against
LNCaP and PC-3 human prostate cancer cell lines (Table
4). Among them, compound 40 showed the most potent
activity, suggesting that introducing a conjugated side
chain in the enol-ketone linker may stabilize the enol-
ketone form as the predominant tautomer (Figure 9),
which may contribute to the anti-prostate cancer activity.
Although the entire structure of the AR has not been fully
determined and the mechanism of how curcumin deriva-
tives interact with the AR is still unclear, preliminary stud-
ies showed that these curcumin derivatives inhibit AR
function via an AR degradation pathway, which plays an
important role in the growth of prostate cancer [82,83]. In
addition, compound 38 (JC-9) with its potent anti-andro-
genic activity and stable physiological properties was
identified as a lead anti-AR compound. Clinical trials
against prostate cancer are being planned.
We prepared four series of new curcumin analogs [81]
including monophenyl curcumin analogs, heterocycle-
containing curcumin analogs, curcumin analogs bearing
various substituents on the phenyl rings, and curcumin
analogs with various linkers, which are being tested for
Schematic diagram of structural features favoring anti-HIV-1  integrase activity Figure 8
Schematic diagram of structural features favoring 
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their anti-prostate cancer activity and action mechanism.
New curcumin analogs from other research groups [84-
86] are also being evaluated for cytotoxic activity against
two human prostate cancer cell lines, i.e. LNCaP and PC-
3, and inhibitory activity to the AR, with goals to elucidate
more refined SAR and optimize curcumin analogs to
develop better anti-prostate cancer drugs.
Conclusion
Natural curcuminoids are compounds found in Curcuma
species, which are used as a medicine of the upper class of
traditional Chinese medicine herbs that are generally not
toxic and are in rich content in natural foods and spices.
Curcuminoids and other natural and synthetic curcumin-
oids possess various bioactivities including anti-inflam-
matory, anti-oxidant, anti-HIV, chemopreventive and
anti-prostate cancer effects. In addition, curcumin was
Structures of JC-9 (38), ECECur (39) and LL-80 (40) with anti-prostate cancer activity Figure 9
Structures of JC-9 (38), ECECur (39) and LL-80 (40) with anti-prostate cancer activity.
Table 4: Cytotoxic activity data of curcumin derivatives against PC-3 and LNCaP prostate cancer cell lines 
Compound R1 R2 PC-3 IC50 (μM)* LNCaP IC50 (μM)*
2 HH 7 . 7 3 . 8
38 CH3 H 1.1 1.3
39 HC H 2CH2COOEt 5.1 1.5
40 CH3 CH=CHCOOEt 1.0 0.2
IC50 values are mean concentrations that inhibit cell growth by 50% (variation between replicates was less than 5%).
IC50 values are expressed as 'means'.
H3CO
R1O
OH O
OR1
OCH3
R2Chinese Medicine 2008, 3:11 http://www.cmjournal.org/content/3/1/11
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recently found to prevent experimental rheumatoid
arthritis [87]. Recent studies on curcuminoids, particu-
larly on curcumin, have discovered not only much on the
therapeutic activities, but also on mechanisms of molecu-
lar biological action and major genomic effects. Our
research group developed some anti-androgenic curcu-
min analogs as anti-prostate cancer agents.
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